Skip to main content
Erschienen in: Cancer Immunology, Immunotherapy 11/2006

01.11.2006 | Original Article

Expression of macrophage-derived chemokine (MDC)/CCL22 in human lung cancer

verfasst von: Toru Nakanishi, Kazuyoshi Imaizumi, Yoshinori Hasegawa, Tsutomu Kawabe, Naozumi Hashimoto, Masakazu Okamoto, Kaoru Shimokata

Erschienen in: Cancer Immunology, Immunotherapy | Ausgabe 11/2006

Einloggen, um Zugang zu erhalten

Abstract

Background: Ligands for CXCR3 chemokines [IFN-γ-inducible protein of 10 kD (IP-10/CXCL10), monokine induced by IFN-γ (Mig/CXCL9), IFN-inducible T cell α chemoattractant (I-TAC/CXCL11)] and those for CCR4 [macrophage-derived chemokine (MDC/CCL22), thymus- and activation-regulated chemokine (TARC/CCL17)] have been shown to play the central roles for T helper-cell recruitment into the tissues. To examine the role of these chemokines in tumor progression of lung cancer, we investigated their expression in human lung cancer tissues to determine the possible relationship between their expression and the prognosis of patients. Methods: Total RNA was prepared from lung cancer tissues of 40 patients (24 adenocarcinoma and 16 squamous cell carcinoma). We measured gene expression levels of chemokines (IP-10, Mig, I-TAC, MDC and TARC) by real-time quantitative RT-PCR. Results: Higher gene expression of MDC in lung cancer was significantly correlated with longer disease-free survival time and lower risk of recurrence after tumor resection. We could not find any significant relationship of IP-10, Mig, I-TAC and TARC gene expression with disease-free survival or lower risk of recurrence after surgery. Conclusions: These results suggest that increased gene expression of MDC in tumor tissues may be a predictive marker for improving the prognosis of lung cancer.
Literatur
1.
Zurück zum Zitat Winterhalder RC, Hirsch FR, Kotantoulas GK, Franklin WA, Bunn PA Jr (2004) Chemoprevention of lung cancer—from biology to clinical reality. Ann Oncol 15:185–196PubMedCrossRef Winterhalder RC, Hirsch FR, Kotantoulas GK, Franklin WA, Bunn PA Jr (2004) Chemoprevention of lung cancer—from biology to clinical reality. Ann Oncol 15:185–196PubMedCrossRef
2.
Zurück zum Zitat Rea F, Marulli G, Callegaro D, Zuin A, Gobbi T, Loy M, Sartori F (2004) Prognostic significance of main bronchial lymph nodes involvement in non-small cell lung carcinoma: N1 or N2? Lung Cancer 45:215–220PubMedCrossRef Rea F, Marulli G, Callegaro D, Zuin A, Gobbi T, Loy M, Sartori F (2004) Prognostic significance of main bronchial lymph nodes involvement in non-small cell lung carcinoma: N1 or N2? Lung Cancer 45:215–220PubMedCrossRef
3.
Zurück zum Zitat Frederick MJ, Clayman GL (2001) Chemokines in cancer. Expert Rev Mol Med 2001:1–18 Frederick MJ, Clayman GL (2001) Chemokines in cancer. Expert Rev Mol Med 2001:1–18
4.
Zurück zum Zitat Arya M, Patel HRH, Williamson M (2003) Chemokines: key players in cancer. Curr Med Res Opin 19:557–564PubMedCrossRef Arya M, Patel HRH, Williamson M (2003) Chemokines: key players in cancer. Curr Med Res Opin 19:557–564PubMedCrossRef
5.
Zurück zum Zitat Van Damme J, Struyf S, Opdenakker G (2004) Chemokine-protease interactions in cancer. Semin Cancer Biol 14:201–208PubMedCrossRef Van Damme J, Struyf S, Opdenakker G (2004) Chemokine-protease interactions in cancer. Semin Cancer Biol 14:201–208PubMedCrossRef
6.
Zurück zum Zitat Opdennakker G, van Damme J (2004) The countercurrent principle in invasion and metastasis of cancer cells. recent insights on the roles of chemokines. Int J Dev Biol 48:519–527CrossRef Opdennakker G, van Damme J (2004) The countercurrent principle in invasion and metastasis of cancer cells. recent insights on the roles of chemokines. Int J Dev Biol 48:519–527CrossRef
7.
Zurück zum Zitat D’Ambrosio D, Mariani M, Panina-Bordignon P, Sinigaglia F (2001) Chemokines and their receptors guiding T lymphocyte recruitment in lung inflammation. Am J Respir Crit Care Med 164:1266–1275PubMed D’Ambrosio D, Mariani M, Panina-Bordignon P, Sinigaglia F (2001) Chemokines and their receptors guiding T lymphocyte recruitment in lung inflammation. Am J Respir Crit Care Med 164:1266–1275PubMed
8.
Zurück zum Zitat Sauty A, Dziejman M, Taha RA, Iarossi AS, Neote K, Garcia-Zepeda EA, Hamid Q, Luster AD (1999) The T cell-specific CXC chemokines IP-10, Mig, and I-TAC are expressed by activated human bronchial epithelial cells. J Immunol 162:3549–3558PubMed Sauty A, Dziejman M, Taha RA, Iarossi AS, Neote K, Garcia-Zepeda EA, Hamid Q, Luster AD (1999) The T cell-specific CXC chemokines IP-10, Mig, and I-TAC are expressed by activated human bronchial epithelial cells. J Immunol 162:3549–3558PubMed
9.
Zurück zum Zitat Qiu B, Frait KA, Reich F, Komuniecki E, Chensue SW (2001) Chemokine expression dynamics in mycobacterial (type-1) and schistosomal (type-2) antigen-elicited pulmonary granuloma formation. Am J Pathol 158:1503–1515PubMed Qiu B, Frait KA, Reich F, Komuniecki E, Chensue SW (2001) Chemokine expression dynamics in mycobacterial (type-1) and schistosomal (type-2) antigen-elicited pulmonary granuloma formation. Am J Pathol 158:1503–1515PubMed
10.
Zurück zum Zitat Carlo ED, Cappello P, Sorrentino C, D’Antuono T, Pellicciotta A, Giovarelli M, Forni G, Musiani P, Triebel F (2005) Immunological mechanisms elicited at the tumour site by lymphocyte activation gene-3 (LAG-3) versus IL-12: sharing a common Th1 anti-tumour immune pathway. J Pathol 205:82–91PubMedCrossRef Carlo ED, Cappello P, Sorrentino C, D’Antuono T, Pellicciotta A, Giovarelli M, Forni G, Musiani P, Triebel F (2005) Immunological mechanisms elicited at the tumour site by lymphocyte activation gene-3 (LAG-3) versus IL-12: sharing a common Th1 anti-tumour immune pathway. J Pathol 205:82–91PubMedCrossRef
11.
Zurück zum Zitat Sekiya T, Miyamasu M, Imanishi M, Yamada H, Nakajima T, Yamaguchi M, Fujisawa T, Pawankar R, Sano Y, Ohta K, Ishii A, Morita Y, Yamamoto K, Matsushima K, Yoshie O, Hirai K (2000) Inducible expression of a Th2-type CC chemokine thymus- and activation-regulated chemokine by human bronchial epithelial cells. J Immunol 165:2205–2213PubMed Sekiya T, Miyamasu M, Imanishi M, Yamada H, Nakajima T, Yamaguchi M, Fujisawa T, Pawankar R, Sano Y, Ohta K, Ishii A, Morita Y, Yamamoto K, Matsushima K, Yoshie O, Hirai K (2000) Inducible expression of a Th2-type CC chemokine thymus- and activation-regulated chemokine by human bronchial epithelial cells. J Immunol 165:2205–2213PubMed
12.
Zurück zum Zitat Ikeda H, Chamoto K, Tsuji T, Suzuki Y, Wakita D, Takeshima T, Nishimura T (2004) The critical role of type-1 innate and acquired immunity in tumor immunotherapy. Cancer Sci 95:697–703PubMedCrossRef Ikeda H, Chamoto K, Tsuji T, Suzuki Y, Wakita D, Takeshima T, Nishimura T (2004) The critical role of type-1 innate and acquired immunity in tumor immunotherapy. Cancer Sci 95:697–703PubMedCrossRef
13.
Zurück zum Zitat Noguchi M, Imaizumi K, Kawabe T, Wakayama H, Horio Y, Sekido Y, Hara T, Hashimoto N, Takahashi M, Shimokata K, Hasegawa Y, (2001) Induction of antitumor immunity by transduction of CD40 ligand gene and interferon-gamma gene into lung cancer. Cancer Gene Ther 8:421–429PubMedCrossRef Noguchi M, Imaizumi K, Kawabe T, Wakayama H, Horio Y, Sekido Y, Hara T, Hashimoto N, Takahashi M, Shimokata K, Hasegawa Y, (2001) Induction of antitumor immunity by transduction of CD40 ligand gene and interferon-gamma gene into lung cancer. Cancer Gene Ther 8:421–429PubMedCrossRef
14.
Zurück zum Zitat White ES, Flaherty KR, Carskadon S, Brant A, Iannettoni MD, Yee J, Orringer MB, Arenberg DA (2003) Macrophage migration inhibitory factor and CXC chemokine expression in non-small cell lung cancer: role in angiogenesis and prognosis. Clin Cancer Res 9:853–860PubMed White ES, Flaherty KR, Carskadon S, Brant A, Iannettoni MD, Yee J, Orringer MB, Arenberg DA (2003) Macrophage migration inhibitory factor and CXC chemokine expression in non-small cell lung cancer: role in angiogenesis and prognosis. Clin Cancer Res 9:853–860PubMed
15.
Zurück zum Zitat Monti P, Leone BE, Marchesi F, Balzano G, Zerbi A, Scaltrini F, Pasquali C, Calori G, Pessi F, Sperti C, Di Carlo V, Allavena P, Piemonti L (2003) The CC chemokine MCP-1/CCL2 in pancreatic cancer progression: regulation of expression and potential mechanisms of antimalignant activity. Cancer Res 63:7451–7461PubMed Monti P, Leone BE, Marchesi F, Balzano G, Zerbi A, Scaltrini F, Pasquali C, Calori G, Pessi F, Sperti C, Di Carlo V, Allavena P, Piemonti L (2003) The CC chemokine MCP-1/CCL2 in pancreatic cancer progression: regulation of expression and potential mechanisms of antimalignant activity. Cancer Res 63:7451–7461PubMed
16.
Zurück zum Zitat Burger M, Glodek A, Hartmann T, Schmitt-Graff A, Silberstein LE, Fujii N, Kipps TJ, Burger JA (2003) Functional expression of CXCR4 (CD184) on small-cell lung cancer cells mediates migration, integrin activation, and adhesion to stromal cells. Oncogene 22:8093–8101PubMedCrossRef Burger M, Glodek A, Hartmann T, Schmitt-Graff A, Silberstein LE, Fujii N, Kipps TJ, Burger JA (2003) Functional expression of CXCR4 (CD184) on small-cell lung cancer cells mediates migration, integrin activation, and adhesion to stromal cells. Oncogene 22:8093–8101PubMedCrossRef
17.
Zurück zum Zitat Tepper RI, Pattengale PK, Leder P (1989) Murine interleukin-4 displays potent anti-tumor activity in vivo. Cell 57:503–512PubMedCrossRef Tepper RI, Pattengale PK, Leder P (1989) Murine interleukin-4 displays potent anti-tumor activity in vivo. Cell 57:503–512PubMedCrossRef
19.
Zurück zum Zitat Guo J, Wang B, Zhang M, Chen T, Yu Y, Regulier E, Homann HE, Qin Z, Ju DW, Cao X (2002) Macrophage-derived chemokine gene transfer results in tumor regression in murine lung carcinoma model through efficient induction of antitumor immunity. Gene Ther 9:793–803PubMedCrossRef Guo J, Wang B, Zhang M, Chen T, Yu Y, Regulier E, Homann HE, Qin Z, Ju DW, Cao X (2002) Macrophage-derived chemokine gene transfer results in tumor regression in murine lung carcinoma model through efficient induction of antitumor immunity. Gene Ther 9:793–803PubMedCrossRef
20.
Zurück zum Zitat Lee JM, Merritt RE, Mahtabifard A, Yamada R, Kikuchi T, Crystal RG, Korst RJ (2003) Intratumoral expression of macrophage-derived chemokine induces CD4+ T cell-independent antitumor immunity in mice. J Immunother 26:117–129PubMedCrossRef Lee JM, Merritt RE, Mahtabifard A, Yamada R, Kikuchi T, Crystal RG, Korst RJ (2003) Intratumoral expression of macrophage-derived chemokine induces CD4+ T cell-independent antitumor immunity in mice. J Immunother 26:117–129PubMedCrossRef
21.
Zurück zum Zitat Ghia P, Transidico P, Veiga JP, Schaniel C, Sallusto F, Matsushima K, Sallan SE, Rolink AG, Mantovani A, Nadler LM, Cardoso AA (2001) Chemoattractants MDC and TARC are secreted by malignant B-cell precursors following CD40 ligation and support the migration of leukemia-specific T cells. Blood 98:533–540PubMedCrossRef Ghia P, Transidico P, Veiga JP, Schaniel C, Sallusto F, Matsushima K, Sallan SE, Rolink AG, Mantovani A, Nadler LM, Cardoso AA (2001) Chemoattractants MDC and TARC are secreted by malignant B-cell precursors following CD40 ligation and support the migration of leukemia-specific T cells. Blood 98:533–540PubMedCrossRef
22.
23.
Zurück zum Zitat Lin EY, Nguyen AV, Russell GR, Pollard JW (2001) Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. J Exp Med 193:727–740PubMedCrossRef Lin EY, Nguyen AV, Russell GR, Pollard JW (2001) Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. J Exp Med 193:727–740PubMedCrossRef
24.
Zurück zum Zitat Daniel D, Meyer-Morse N, Bergsland EK, Dehne K, Coussens LM, Hanahan D (2003) Immune enhancement of skin carcinogenesis by CD4+ T cells. J Exp Med 197:1017–1028PubMedCrossRef Daniel D, Meyer-Morse N, Bergsland EK, Dehne K, Coussens LM, Hanahan D (2003) Immune enhancement of skin carcinogenesis by CD4+ T cells. J Exp Med 197:1017–1028PubMedCrossRef
25.
Zurück zum Zitat Arenberg DA, Kunkel SL, Polverini PJ, Morris SB, Burdick MD, Glass MC, Taub DT, Iannettoni MD, Whyte RI, Strieter RM (1996) Interferon-gamma-inducible protein 10 (IP-10) is an angiostatic factor that inhibits human non-small cell lung cancer (NSCLC) tumorigenesis and spontaneous metastases. J Exp Med 184:981–992PubMedCrossRef Arenberg DA, Kunkel SL, Polverini PJ, Morris SB, Burdick MD, Glass MC, Taub DT, Iannettoni MD, Whyte RI, Strieter RM (1996) Interferon-gamma-inducible protein 10 (IP-10) is an angiostatic factor that inhibits human non-small cell lung cancer (NSCLC) tumorigenesis and spontaneous metastases. J Exp Med 184:981–992PubMedCrossRef
26.
Zurück zum Zitat Kondo T, Ito F, Nakazawa H, Horita S, Osaka Y, Toma H (2004) High expression of chemokine gene as a favorable prognostic factor in renal cell carcinoma.. J Urol 171:2171–2175PubMedCrossRef Kondo T, Ito F, Nakazawa H, Horita S, Osaka Y, Toma H (2004) High expression of chemokine gene as a favorable prognostic factor in renal cell carcinoma.. J Urol 171:2171–2175PubMedCrossRef
27.
Zurück zum Zitat Okada N, Gao JQ, Sasaki A, Niwa M, Okada Y, Nakayama T, Yoshie O, Mizuguchi H, Hayakawa T, Fujita T, Yamamoto A, Tsutsumi Y, Mayumi T, Nakagawa S (2004) Anti-tumor activity of chemokine is affected by both kinds of tumors and the activation state of the host’s immune system: implications for chemokine-based cancer immunotherapy. Biochem Biophys Res Commun 317:68–76PubMedCrossRef Okada N, Gao JQ, Sasaki A, Niwa M, Okada Y, Nakayama T, Yoshie O, Mizuguchi H, Hayakawa T, Fujita T, Yamamoto A, Tsutsumi Y, Mayumi T, Nakagawa S (2004) Anti-tumor activity of chemokine is affected by both kinds of tumors and the activation state of the host’s immune system: implications for chemokine-based cancer immunotherapy. Biochem Biophys Res Commun 317:68–76PubMedCrossRef
28.
Zurück zum Zitat Berin MC, Eckmann L, Broide DH, Kagnoff MF (2001) Regulated production of the T helper 2-type T-cell chemoattractant TARC by human bronchial epithelial cells in vitro and in human lung xenografts. Am J Respir Cell Mol Biol 24:382–389PubMed Berin MC, Eckmann L, Broide DH, Kagnoff MF (2001) Regulated production of the T helper 2-type T-cell chemoattractant TARC by human bronchial epithelial cells in vitro and in human lung xenografts. Am J Respir Cell Mol Biol 24:382–389PubMed
29.
Zurück zum Zitat Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, Evdemon-Hogan M, Conejo-Garcia JR, Zhang L, Burow M, Zhu Y, Wei S, Kryczek I, Daniel B, Gordon A, Myers L (2004) Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 10:942–949PubMedCrossRef Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, Evdemon-Hogan M, Conejo-Garcia JR, Zhang L, Burow M, Zhu Y, Wei S, Kryczek I, Daniel B, Gordon A, Myers L (2004) Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 10:942–949PubMedCrossRef
30.
Zurück zum Zitat Arriagada R, Bergman B, Dunant A, Le Chevalier T, Pignon JP, Vansteenkiste J (2004) Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 350:351–360PubMedCrossRef Arriagada R, Bergman B, Dunant A, Le Chevalier T, Pignon JP, Vansteenkiste J (2004) Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 350:351–360PubMedCrossRef
31.
Zurück zum Zitat Kato H, Ichinose Y, Ohta M, Hata E, Tsubota N, Tada H, Watanabe Y, Wada H, Tsuboi M, Hamajima N (2004) A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. N Engl J Med 350:1713–1721PubMedCrossRef Kato H, Ichinose Y, Ohta M, Hata E, Tsubota N, Tada H, Watanabe Y, Wada H, Tsuboi M, Hamajima N (2004) A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. N Engl J Med 350:1713–1721PubMedCrossRef
Metadaten
Titel
Expression of macrophage-derived chemokine (MDC)/CCL22 in human lung cancer
verfasst von
Toru Nakanishi
Kazuyoshi Imaizumi
Yoshinori Hasegawa
Tsutomu Kawabe
Naozumi Hashimoto
Masakazu Okamoto
Kaoru Shimokata
Publikationsdatum
01.11.2006
Verlag
Springer-Verlag
Erschienen in
Cancer Immunology, Immunotherapy / Ausgabe 11/2006
Print ISSN: 0340-7004
Elektronische ISSN: 1432-0851
DOI
https://doi.org/10.1007/s00262-006-0133-y

Weitere Artikel der Ausgabe 11/2006

Cancer Immunology, Immunotherapy 11/2006 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.